IBM Analysis of HAIs in Mexico
Our report explores the prevalence, causes, and potential prevention strategies for infections in healthcare settings in Mexico.
For more information, refer to the attached file.
Related Articles
Corporate Brochures for IBM
Ion Biotechnology México S.A. de C.V. is dedicated to bringing the benefits of Ion Biotechnology Aqueous Ligands (IBAL) to Latino markets. Our aim is to expand throughout Central and South American regions, ensuring widespread access to these ...
Ion Biotechnology Mexico Corporate Brochure
Ion Biotechnology México S.A de C.V. is focused on introducing Ion Biotechnology Aqueous Ligands (IBAL) to Latino markets in Central and South America, with the goal of ensuring widespread access to innovative therapies. Our strategic approach ...
Ion Gel ZCM-25® Presentation
ION-ZCM1, the IBAL-based active pharmaceutical ingredient (API) in Ion Gel ZCM-25®, is a unique coordination complex of ligands in a redox solution of hexaaqua ions containing zinc, copper, and magnesium, as well as sulfur, and hydrogen. For more ...
Efficacy of Ion Gel ZCM-25® in the Antiviral Treatment Against Dengue Virus
Background: Dengue virus is a significant pathogen responsible for various infections, particularly in healthcare environments, and presents substantial treatment challenges. The necessity for effective antiviral agents against Dengue is critical. ...
Ion Gel ZCM-25® Expanded Provider User Manual for Healthcare Providers
Surgical Site Infections (SSIs) are a significant concern in healthcare settings, accounting for a significant portion of healthcare-associated infections (HAIs) and resulting in increased costs, morbidity, and mortality. The use of topical ...